Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.44 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.36 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 3/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16939391 | 0.87 | TAAR1 (0.39) | TAAR1AKR1B1SMN1; SMN2HPGDLMNA | |
| SCHEMBL6984300 | 0.85 | TAAR1 (0.55) | TAAR1SMN1; SMN2GAAHTTNPSR1 | |
| SCHEMBL18419796 | 0.82 | P2RX7 (0.39) | TAAR1NR3C1NR3C2KMT2A | |
| SCHEMBL20428033 | 0.79 | TAAR1 (0.40) | TAAR1AKR1B1SMN1; SMN2HPGDCYP1A2 | |
| SCHEMBL10026846 | 0.78 | ESR1 (0.33) | — | |
| SCHEMBL11567106 | 0.77 | TAAR1 (0.46) | TAAR1AKR1B1SMN1; SMN2CYP1A2CYP2A6 | |
| SCHEMBL21782546 | 0.76 | HPGD (0.33) | TAAR1AKR1B1SMN1; SMN2HPGDCYP1A2 | |
| SCHEMBL11910297 | 0.76 | TAAR1 (0.52) | TAAR1AKR1B1SMN1; SMN2HPGDCYP1A2 | |
| SCHEMBL3912635 | 0.76 | TAAR1 (0.38) | TAAR1AKR1B1SMN1; SMN2HPGDCYP1A2 | |
| SCHEMBL10026852 | 0.75 | ALDH1A1 (0.39) | SMN1; SMN2HPGDTSHRHTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-3031229-A | — | — | None | — | — | JP | disclosed |
| EP-3743430-B1 | AMINOPYRROLOTRIAZINES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2023-08-02 | — | — | EP | disclosed |
| US-20200347071-A1 | AMINOPYRROLOTRIAZINES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-11-05 | — | — | US | disclosed |
| EP-3275867-B1 | PYRIDO-FUSED BICYCLIC COMPOUNDS AS URAT1 INHIBITORS FOR TREATING HYPERURICEMIA | SHANGHAI YINGLI PHARM CO LTD (CN) | 2020-06-10 | — | — | EP | disclosed |
| US-10329283-B2 | G protein-coupled receptor kinase inhibitors and methods for use of the same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2019-06-25 | — | — | US | disclosed |
| US-10035790-B2 | RORγ modulators | EXELIXIS, INC. (US) | 2018-07-31 | — | — | US | disclosed |
| US-10023564-B2 | G protein-coupled receptor kinase 2 inhibitors and methods for use of the same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2018-07-17 | — | — | US | disclosed |
| US-20180186779-A1 | G PROTEIN-COUPLED RECEPTOR KINASE INHIBITORS AND METHODS FOR USE OF THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2018-07-05 | — | — | US | disclosed |
| US-20180186779-A1 | G PROTEIN-COUPLED RECEPTOR KINASE INHIBITORS AND METHODS FOR USE OF THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2018-07-05 | — | — | US | disclosed |
| US-20180072678-A1 | CONDENSED RING DERIVATIVE, AND PREPARATION METHOD, INTERMEDIATE, PHARMACEUTICAL COMPOSITION AND USE THEREOF | SHANGHAI YINGLI PHARMACEUTICAL CO., LTD. (CN) | 2018-03-15 | — | — | US | disclosed |
| US-20080051447-A1 | Treatment Of Hypercholesterolemia, Hypertriglyceridemia And Cardiovascular-Related Conditions Using Phospholipase-A2 Inhibitors | ILYPSA, INC. | 2008-02-28 | — | — | US | disclosed |
| US-20080021049-A1 | Treatment Of Diet-Related Conditions Using Phospholipase-A2 Inhibitors Comprising Indoles And Related Compounds | ILYPSA, INC. | 2008-01-24 | — | — | US | disclosed |
| US-20070292385-A1 | Phospholipase Inhibitors Localized in the Gastrointestinal Lumen | ILYPSA, INC. | 2007-12-20 | — | — | US | disclosed |
| US-7291612-B2 | Immunomodulatory compounds | ACTIVE BIOTECH A.B. (SE) | 2007-11-06 | — | — | US | disclosed |
| WO-2007083207-A1 | SUBSTITUTED IMIDAZOLES AND THEIR USE AS PESTICIDES | PFIZER LIMITED (GB) | 2007-07-26 | — | — | WO | disclosed |
| US-20070167506-A1 | SUBSTITUTED IMIDAZOLES | PFIZER INC. (US) | 2007-07-19 | — | — | US | disclosed |
| US-20070135385-A1 | Methyl indoxam; obesity; dietectics; antidiabetic agents; insulin resistance; non-insulin dependent diabetes; glucose intolerance; hypercholesterolemia; hypertriglyceridemia; anticholesterol agents; metabolic disorders; foods;bioavailability; side effect reduction | ILYPSA, INC. | 2007-06-14 | — | — | US | disclosed |
| US-20070135383-A1 | Phospholipase inhibitors, including multi-valent phospholipase inhibitors, and use thereof, including as lumen-localized phospholipase inhibitors | ILYPSA, INC. | 2007-06-14 | — | — | US | disclosed |
| US-20070135383-A1 | Phospholipase inhibitors, including multi-valent phospholipase inhibitors, and use thereof, including as lumen-localized phospholipase inhibitors | ILYPSA, INC. | 2007-06-14 | — | — | US | disclosed |
| JP-H0331229-A | PRODUCTION OF 2,6-DICHLOROTOLUENE | IDEMITSU KOSAN CO LTD | 1991-02-12 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10035790-B2 | RORγ modulators | RORB, RORA, RORC | TAAR1 1070/4885AKR1B1 218/4885SMN1; SMN2 3896/4885 |
| US-20070135385-A1 | Methyl indoxam; obesity; dietectics; antidiabetic agents; insulin resistance; non-insulin dependent diabetes; glucose intolerance; hypercholesterolemia; hypertriglyceridemia; anticholesterol agents; metabolic disorders; foods;bioavailability; side effect reduction | GPR119, INMT, PNLIP | TAAR1 1967/4885AKR1B1 369/4885SMN1; SMN2 4718/4885 |
| US-20200347071-A1 | AMINOPYRROLOTRIAZINES AS KINASE INHIBITORS | RIPK1, RIPK2, RIPK4 | TAAR1 3381/4885AKR1B1 2585/4885SMN1; SMN2 4059/4885 |
| US-10329283-B2 | G protein-coupled receptor kinase inhibitors and methods for use of the same | GRK2, GRK4, GRK3 | TAAR1 804/4885AKR1B1 1565/4885SMN1; SMN2 4674/4885 |
| US-20180186779-A1 | G PROTEIN-COUPLED RECEPTOR KINASE INHIBITORS AND METHODS FOR USE OF THE SAME | GRK2, GRK4, GRK3 | TAAR1 804/4885AKR1B1 1565/4885SMN1; SMN2 4674/4885 |
| US-10023564-B2 | G protein-coupled receptor kinase 2 inhibitors and methods for use of the same | GRK2, GRK4, GRK5 | TAAR1 844/4885AKR1B1 1873/4885SMN1; SMN2 4310/4885 |
| US-20070135383-A1 | Phospholipase inhibitors, including multi-valent phospholipase inhibitors, and use thereof, including as lumen-localized phospholipase inhibitors | PNLIP, PLA2G2E, PLA2G3 | TAAR1 2565/4885AKR1B1 1398/4885SMN1; SMN2 4155/4885 |
| US-20070167506-A1 | SUBSTITUTED IMIDAZOLES | ABL1, TYR, CYP3A4 | TAAR1 2147/4885AKR1B1 2006/4885SMN1; SMN2 1394/4885 |
| US-20080021049-A1 | Treatment Of Diet-Related Conditions Using Phospholipase-A2 Inhibitors Comprising Indoles And Related Compounds | PLA2G12A, PLA2G4A, PLA2G2E | TAAR1 663/4885AKR1B1 201/4885SMN1; SMN2 3821/4885 |
| US-20070292385-A1 | Phospholipase Inhibitors Localized in the Gastrointestinal Lumen | PNLIP, PLA2G2E, PLA2G4B | TAAR1 1897/4885AKR1B1 845/4885SMN1; SMN2 4186/4885 |
| US-20180072678-A1 | CONDENSED RING DERIVATIVE, AND PREPARATION METHOD, INTERMEDIATE, PHARMACEUTICAL COMPOSITION AND USE THEREOF | URB2, UGP2, NLRP3 | TAAR1 3781/4885AKR1B1 495/4885SMN1; SMN2 4594/4885 |
| US-20080051447-A1 | Treatment Of Hypercholesterolemia, Hypertriglyceridemia And Cardiovascular-Related Conditions Using Phospholipase-A2 Inhibitors | PNLIP, PLA2G1B, PLA2G4A | TAAR1 2382/4885AKR1B1 561/4885SMN1; SMN2 4701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.